Drawing for COMPLEX CHALLENGES. EXCEPTIONAL SOLUTIONS.

USPTO serial 87565901

COMPLEX CHALLENGES. EXCEPTIONAL SOLUTIONS.

Reviewed by CopyMark Law Group

Reg. 5602592Status 702Registered
Filing date
Status date
Registration date
Nov 6, 2018
Examiner
SANTOMARTINO, MARTHA L
Law office
Historical data usage

What this means

Status 702 means the registration is active, Section 8 was accepted, and a Section 15 declaration of incontestability was also accepted. Incontestability strengthens your rights by limiting certain challenges after five years of continuous use. Continue use in commerce and plan for the 10-year Section 8 and 9 renewal.

Status 702: Status 702 means the registration is active, Section 8 was accepted, and a Section 15 declaration of incontestability was also accepted. Incontestability strengthens your rights by limiting certain challenges after five years of continuous use.

Need help with COMPLEX CHALLENGES. EXCEPTIONAL SOLUTIONS.?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Dianne M. Smith-Misemer

Dianne M. Smith-Misemer HOVEY WILLIAMS LLP10801 Mastin St., Suite 1000Overland Park, KS 66210United States

Goods and services

ClassDescriptionStatusFirst use
035Business information and business consulting services, namely, providing business advisory services to identify, screen, and select contract manufacturing organizations to contract and build medical and pharmaceutical products and devices; providing business advisory services to health care providers, namely, designing the administrative, financial and clinical workflows associated with value-based healthcare delivery models; providing business assistance to healthcare providers in the field of enabling communication and collaboration for the purpose of developing, implementing and evaluating patient care plans; Business services, namely, tracking and monitoring regulatory requirements in the pharmaceutical, biotechnology, and medical fields for business purposesACTIVEJan 1, 2018
042Providing quality assurance services in the medical, pharmaceutical, and biotechnology fields; Quality management services, namely, quality evaluation and analysis, quality assurance, and quality control, in the medical, pharmaceutical, and biotechnology fields; Testing, analysis, and evaluation of medical, pharmaceutical, and biotechnology services to assure compliance with industry standards; Tracking and monitoring regulatory requirements in the pharmaceutical, biotechnology, and medical fields for quality control purposesACTIVEJan 1, 2018
044Consulting services in the medical, pharmaceutical, and biotechnology fields; providing medical and pharmaceutical information services, namely, drug interaction call centers, adverse event reporting services for drugs and medical devices and product compliant reporting services for drugs and medical device; medical information; providing medical information, consultancy and advisory services; health care consulting, namely, aggregating clinical, claims, socioeconomic and behavioral health data for the purpose of improving healthcare providers' evaluation of health conditions and health risks with individual patients, cohorts of patients, and populations; health care consulting, namely, assessing patient and population health profiles using evidence-based medical guidelines for the purpose of improving healthcare provider treatment decisions at the point of care; providing information over a global computer network in the field of health care; maintaining files and records concerning the medical condition of individuals; maintaining personal medical history records and files; providing medical information, consultancy, and advisory services, namely, providing healthcare providers, insurance companies, and healthcare product manufacturers with information and statistics regarding patient medication intake, schedule compliance, and health statusACTIVEJan 1, 2018
045Regulatory compliance consulting in the pharmaceutical, biotechnology, and medical fields; Regulatory compliance consulting in the fields of drug and device development and manufacturing; Tracking and monitoring regulatory requirements in the pharmaceutical, biotechnology, and medical fields for legal or regulatory compliance purposes; Tracking and monitoring regulatory requirements in the field of drug and device development and manufacturing for regulatory compliance purposesACTIVEJan 1, 2018

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Mar 27, 2026EWAFTEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS—
Mar 27, 2026TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Mar 27, 2026ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Mar 27, 2026REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Sep 23, 2025TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Sep 23, 2025ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Sep 23, 2025REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Sep 23, 2025CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
Sep 23, 2025COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
Jun 3, 2024NA85NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED—
Jun 3, 2024C15AREGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.—
Jun 3, 2024APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
Nov 27, 2023E815TEAS SECTION 8 & 15 RECEIVED—
Nov 6, 2023REM1COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED—
Nov 6, 2018R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Oct 2, 2018SUNANOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED—
Oct 1, 2018CNPRALLOWED PRINCIPAL REGISTER - SOU ACCEPTED—
Sep 8, 2018SUPCSTATEMENT OF USE PROCESSING COMPLETE—
Sep 7, 2018AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
Aug 9, 2018IUAFUSE AMENDMENT FILED—
Aug 9, 2018EISUTEAS STATEMENT OF USE RECEIVEDThe applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action.
Apr 3, 2018NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Feb 6, 2018NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Feb 6, 2018PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Jan 17, 2018NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Dec 30, 2017CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Dec 30, 2017XAECEXAMINER'S AMENDMENT ENTERED—
Dec 30, 2017GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Dec 30, 2017GNEAEXAMINERS AMENDMENT E-MAILED—
Dec 30, 2017CNEAEXAMINERS AMENDMENT -WRITTEN—
Dec 28, 2017TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Dec 28, 2017CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Dec 21, 2017TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Nov 15, 2017GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Nov 15, 2017GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Nov 15, 2017CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Nov 14, 2017DOCKASSIGNED TO EXAMINER—
Aug 31, 2017TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Aug 31, 2017CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Aug 31, 2017ALIEASSIGNED TO LIE—
Aug 18, 2017NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Aug 15, 2017PARITEAS VOLUNTARY AMENDMENT RECEIVED—
Aug 15, 2017NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance